Jack,
Thanks for the updates. It will be interesting to see what changes take place among the analysts in the near-term, if any. Webber has consistently been a bull with that 32 target, including through the tough times of Hecht downgrading...different ends of the spectrum.
Others potentially interesting to keep an eye on:
One of the analysts who had followed ATIS a while back from Principal Financial...I think it is Bill Tanner....has switched employment... I think to Vector. This may mean nothing, but it's something to watch for. Also, there is a Thursday evening discussion through one of the companies, I think Donaldson, Lufkin and Jenrette, highlighting ?21 companies with fda panel prospects. Haven't heard any of the specifics as to how this is being/to be done, but I have been told that one of the ?21 is ATIS.
I believe ATIS has already done some type of pilot study a few years back(?94&/or 95) with venous stasis ulcers, but I don't recall any of the specifics. They had said they would be looking at doing at least venous stasis or pressure sores at some point starting this year, but I hadn't heard that they had decided for sure yet as to which. ARe you sure about the venous stasis?
For the shorts to relinquish some control, there needs to be either continue gradual following through with meeting expectations, or some things which are ahead of schedule or pleasant surprises along the way. Otherwise, as Harry had said a while back, there are brakes slowing this down.
Take care,
Marshall |
